Xuanzhu Biopharmaceutical Announces Positive Phase III Results for Dirozalkib in ALK-Positive Advanced Non-Small Cell Lung Cancer

Key Highlights from the Report

• Xuanzhu Biopharmaceutical Co., Ltd. presented breakthrough Phase III clinical data for its novel ALK inhibitor, Dirozalkib, at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
• The study, known as DIAMOND-2 (NCT05204628), was a head-to-head trial against crizotinib, the current standard first-line therapy for ALK-positive advanced non-small cell lung cancer (NSCLC).
• Dirozalkib demonstrated highly significant improvements in efficacy endpoints including progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), and intracranial efficacy compared to crizotinib.
• Safety data showed a favorable profile, with very few patients discontinuing due to drug-related adverse events.
• Dirozalkib was approved by the NMPA in August 2025 for first-line treatment of ALK-positive locally advanced or metastatic NSCLC.

Detailed Review of Clinical Results

The DIAMOND-2 trial was a multicenter, randomized, open-label Phase III study conducted in China. A total of 275 patients with ALK-positive advanced NSCLC were enrolled and randomized 1:1 to receive either dirozalkib (500 mg once daily) or crizotinib (250 mg twice daily).

• Primary Endpoint – Progression-Free Survival (PFS):
  • Median PFS for dirozalkib was 31.3 months, compared to 12.9 months for crizotinib—a striking improvement.
  • This translates to a 53% reduction in the risk of disease progression (Hazard Ratio = 0.47, P < 0.0001), which is both statistically and clinically significant.
• Secondary Endpoints:
  • Objective Response Rate (ORR): Dirozalkib achieved an ORR of 88.5%.
  • Median Duration of Response (DoR): Reported at 32.1 months.
  • Disease Control Rate (DCR): Achieved at 95.4%, indicating deeper and longer-lasting tumor responses compared to the control group.
• Intracranial Efficacy:
  • Among patients with measurable brain metastases at baseline, intracranial ORR (IC-ORR) was 91.7% for dirozalkib versus just 11.1% for crizotinib.
  • Dirozalkib significantly prolonged intracranial PFS and reduced the risk of intracranial disease progression by 55% (HR = 0.45, P = 0.0003).
• Safety:
  • Dirozalkib’s safety profile was favorable, with primarily mild (Grade 1–2) gastrointestinal adverse events.
  • Only 1.5% of patients discontinued therapy due to drug-related adverse events, supporting its strong safety profile.

About Dirozalkib (Xuan Fei Ning)

• Dirozalkib is a next-generation, oral ALK inhibitor developed by Xuanzhu Biopharmaceutical.
• It features a novel molecular structure with high affinity for the ATP-binding site of the ALK kinase domain.
• Demonstrates potent inhibition against resistance mutations common with first- and most second-generation ALK inhibitors, including G1202R and I1171N.
• Shows strong penetration of the blood-brain barrier, translating to significant intracranial anti-tumor efficacy.
• Received NMPA approval in August 2025 for first-line treatment of ALK-positive locally advanced or metastatic NSCLC in patients who have not received prior ALK inhibitor therapy.

Potential Impact for Shareholders and Investors

• Significant clinical superiority over crizotinib positions dirozalkib as a potential new standard of care for first-line treatment of ALK-positive advanced NSCLC in China and potentially other markets.
• Regulatory approval and positive data support commercial uptake, which could drive substantial revenue growth and market share gains for Xuanzhu Biopharmaceutical.
• Strong intracranial efficacy and favorable safety profile address key unmet needs in ALK-positive NSCLC, further enhancing the product’s competitive edge.
• These results are likely to be price sensitive and may positively impact the company’s share price, as they reinforce Xuanzhu’s leadership in innovative oncology treatments and expand its opportunities for market expansion.

Board Information

As of the announcement date, Xuanzhu Biopharmaceutical’s board is chaired by Ms. Xu Yanjun, with a team of experienced executive, non-executive, and independent non-executive directors.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Please consult professional advisors before making any investment decisions.

View XUANZHUBIO-B Historical chart here